Oral tazarotene and oral pimecrolimus: novel oral therapies in development for psoriasis.
Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European population. Over the last several years, one of the major focuses in psoriasis research has been the development of novel biologic therapies for this disease. The aim of these therapies is to provide selective, immunologically directed intervention, with the hope that such specificity will result in fewer side effects than traditional therapies. In addition to these therapies, there are also oral medications in development for psoriasis. The goal of this article is to review oral tazarotene, a novel retinoid, and oral pimecrolimus, a novel macrolactam therapy, for the treatment of moderate to severe psoriasis.
Singh
Fiza
F
Department of Dermatology, ST. Luke's-Roosevelt Hospital Center, New York, New York 10025, USA.
Weinberg
Jeffrey M
JM
D000284:Administration, Oral; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy*; D016559:Tacrolimus / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D012176:Retinoids
D003879:Dermatologic Agents; D009539:Nicotinic Acids; D016559:Tacrolimus; C117268:pimecrolimus; C086827:tazarotene; D012176:Retinoids